B7-H3 immunoregulatory roles in cancer.
B7 homolog 3 (B7-H3)
Cancer
Programmed death-ligand 1 (PD-L1)
Resistance
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
04
2023
revised:
06
05
2023
accepted:
12
05
2023
medline:
29
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of B7 family that is aberrantly and consistently expressed in several human cancers, and its overexpression correlates with weak prognosis. B7-H3 is expressed on a number of cells, and it acts as a driver of immune evasion. This is mediated through hampering T cell infiltration and promoting exhaustion of CD8
Identifiants
pubmed: 37196544
pii: S0753-3322(23)00680-7
doi: 10.1016/j.biopha.2023.114890
pii:
doi:
Substances chimiques
B7 Antigens
0
Antibodies, Monoclonal
0
CD276 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114890Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.